Myriad touts 10-year data for prostate cancer screen

Myriad HQ
The study found that the higher a patient’s Prolaris test score, the higher his risk for metastasis.

Myriad Genetics unveiled new data showing its prostate cancer diagnostic could accurately predict the 10-year risk of metastasis in men who have been treated for the disease.

The test, Prolaris, is an RNA-expression test that looks at individual patients’ risk of developing prostate cancer, which may be used to determine the course of treatment.

The new study, which will be presented at the American Urological Association’s annual meeting, followed 767 men with localized prostate cancer, according to a statement. They underwent the Prolaris test to predict the risk of metastatic disease up to 10 years after diagnosis.


Webinar: The Key to Continuous Compliance for Medical Device Software Developers

Risk is not an option in medical device software development. You need to mitigate time-to-market, FDA, and security risks, or you could be facing a costly recall or software update. Attend this webinar to learn how to use static analysis to ensure continuous compliance with industry standards and regulatory requirements, improve security for increasingly connected medical devices, and enforce corporate and industry coding rules and best practices.

The data show that 5% of the patients developed metastases, while 4.3% of the patients who had undergone definitive treatment—surgery, radiation, or radiation and hormones—developed metastases, the company said.

The study found that the higher a patient’s Prolaris test score, the higher his risk for metastasis—each one-unit increase in score correlated with nearly triple the risk.

“Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Stephen Bardot, M.D., who conducted the study. “This study also included a large group of [African-American] men which have historically been underrepresented in clinical outcomes studies. This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African-American and non-African-Americans equally.”

Now, Myriad will include metastasis risk in the Prolaris test report.

“We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.,” said Michael Brawer, M.D., Myriad’s senior vice president of medical affairs, in the statement. We are excited to provide all of this relevant information in a single test report for clinicians.”

Suggested Articles

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO.

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.

Bayer is teaming up with a Swedish digital health startup focused on boosting patient compliance with an internet-connected pillbox.